ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,414Medicare Part D Prescriptions Filled, Including Refills

Rank: 758 out of 5176

$822K Total Retail Price of All Prescriptions

Rank: 421 out of 5176

452 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 452 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

4% of this provider’s 452 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

2% of this provider’s 8,516 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

37% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$87 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
SIMVASTATIN 364 333 1 1
METOPROLOL TARTRATE 233 204 2 6
ATELVIA 221 214 3 146
AMLODIPINE BESYLATE 220 198 4 2
WARFARIN SODIUM 208 176 5 13
FUROSEMIDE 202 189 6 8
LEVOTHYROXINE SODIUM 179 170 7 4
CRESTOR 159 146 8 15
OMEPRAZOLE 141 119 9 3
CITALOPRAM HBR 138 125 10 31
ATORVASTATIN CALCIUM 134 131 11 9
ZOLPIDEM TARTRATE 128 126 12 17
NEXIUM 110 91 13 16
LOSARTAN-HYDROCHLOROTHIAZIDE 109 104 14 35
MELOXICAM 104 98 15 53
LISINOPRIL 104 92 15 5
ATENOLOL 98 98 17 12
ESCITALOPRAM OXALATE 95 95 18 89
PANTOPRAZOLE SODIUM 89 86 19 61
BENICAR HCT 87 86 20 110
MICARDIS HCT 87 76 20 180
CARVEDILOL 87 86 20 24
METOPROLOL SUCCINATE 85 61 23 11
CLOTRIMAZOLE-BETAMETHASONE 84 77 24 94
POTASSIUM CHLORIDE 84 78 24 34
LOSARTAN POTASSIUM 84 68 24 14
METFORMIN HCL 84 62 24 7
TAMSULOSIN HCL 78 78 28 20
SERTRALINE HCL 77 70 29 30
MIRTAZAPINE 76 73 30 45
CIPROFLOXACIN HCL 74 70 31 84
GABAPENTIN 74 72 31 21
HYDROCHLOROTHIAZIDE 74 74 31 10
AZITHROMYCIN 61 54 34 42
ALPRAZOLAM 59 59 35 259
OXYCODONE-ACETAMINOPHEN 58 45 S2 36 101
LYRICA 57 42 37 133
PLAVIX 57 48 37 29
KLOR-CON M20 56 56 39 129
MECLIZINE HCL 55 55 40 81
TRAMADOL HCL-ACETAMINOPHEN 55 55 40 116
TRIAMTERENE-HYDROCHLOROTHIAZID 55 52 40 317
METHYLPREDNISOLONE 54 50 43 218
FENOFIBRATE 53 42 44 102
CYMBALTA 53 49 44 90
ISOSORBIDE MONONITRATE ER 53 38 44 44
BENICAR 53 53 44 100
LUNESTA 53 53 44 242
NASONEX 53 53 44 178
TRICOR 52 34 50 148
DIOVAN 52 52 50 19
ZETIA 51 49 52 68
QUETIAPINE FUMARATE 51 47 52 75
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 9, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.